Skip to Content

Posts tagged with "Pharmacokinetics"

  • Clinical Trials

    Ultrasound For Brain Drug Delivery – Not So Fast

    I wrote a couple of years ago here about the idea of making the blood-brain barrier more permeable by the use of focused ultrasound, in the presence of injected microbubbles. This would be a very useful thing if it works – as anyone who’s been concerned with central nervous system drugs (or drug delivery in… Read More
  • Cancer

    What We Can Do, Versus What We Could

    I remember reading Barry Sharpless’ big “click” chemistry paper in 2001, where he proposed the term for reactions that take place rapidly, selectively, and without any outside reagents, and proposed such techniques for the rapid assembly of diverse molecules. In the years since, the term has drifted away a bit at times to mean … Read More
  • Biological News

    Turmoil in Immuno-oncology

    Immuno-oncology! It’s such a big deal, let’s just do what everyone in the field is doing and call it “IO”. The recent successes in this area have rearranged every company’s oncology strategy, in some cases rearranging its entire oncology portfolio right out the door. There are several possibilities open to you now, if… Read More
  • Pharmacokinetics

    The First Deuterated Drug Arrives

    The first deuterated drug has finally been approved by the FDA. It’s Austedo (deutetrabenazine), from Teva, and it targets Huntington’s chorea. This is an interesting development on several levels. The idea of adding deuteriums (instead of plain hydrogens) to drug structures had been kicking around for many years, but only in the last 8… Read More
  • Chemical News

    Macrocycles For the Making

    I meant to write about this paper at the time, but there’s no harm in highlighting it now. A group at the University of Toronto reports a neat way to make some unusual macrocycles, by closing down an amine and a carboxylic acid into an oxadiazole with the known isonitrile phosphorane reagent shown. You bring… Read More
  • How Not to Do It

    How Not to Do It: Dosing Volunteers

    Well, here I post about the ethical problems of using normal volunteers in Phase I studies, and this story comes along. It’s not exactly an investigational drug trial – two students (in “Sports Science”) at Northumbria University in England were being given caffeine to measure its effects on exercise. But there was a bit of… Read More
  • Chemical Biology

    Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natural product, found in large quantities in turmeric root (which is where most of the yellow color comes from). It has, over the years, been a hit in many, many assays, and… Read More
  • Alzheimer's Disease

    A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More
  • "Me Too" Drugs

    Isotope Labeling For Fun and Profit

    Here’s an article on a company called Molecular Isotope Technologies, and their bid to “revolutionize the drug industry”. From the name, you might expect that this is another deuterium-for-proton idea, and you would say to yourself “But that’s already been done”. But read on. The company is perhaps better known b… Read More
  • Cancer

    Nanoparticles Mix It Up With Reality

    Nanoparticles (well, papers about nanoparticles) have been impossible to avoid for. . .what, ten years now, would you say? There’s so much potential there in so many fields, and there are so many things to try, that the literature is a gigantic pile that gets more deliveries dumped on it every week. And how many… Read More
...234...